Lyka Labs Sees Strong Q1 Growth, Approves Subsidiary Divestment

Standalone Revenue: ₹42.31 crore | Net Profit: ₹2.10 crore

Reader Takeaway: Strong revenue and profit growth; strategic divestment of a loss-making subsidiary.

What just happened

Lyka Labs has announced a robust financial performance for the first quarter ended June 30, 2026. Standalone revenue from operations surged by 45% year-on-year to ₹42.31 crore, compared to ₹29.18 crore in the same period last year. Net profit after tax saw an even more significant jump of 159.3%, reaching ₹2.10 crore from ₹0.81 crore in Q1 FY25. The company also received board approval to divest its entire 100% equity stake in its subsidiary, Lyka BDR International Limited.

Why this matters

The strong revenue and profit growth indicate improved operational performance and market traction for Lyka Labs. The strategic divestment of Lyka BDR International Limited, which had a negative net worth, suggests a focus on streamlining the company's portfolio and enhancing overall financial health and profitability.

The backstory

This quarter's performance follows a period of strategic adjustments for Lyka Labs. Earlier in the year, the National Company Law Tribunal (NCLT) sanctioned the Scheme of Amalgamation for the merger of Lyka Export Limited with Lyka Labs Limited, effective March 16, 2026. The auditors, D. Kothary & Co., have provided an unmodified conclusion on the financial results, indicating no significant concerns from their review.

What changes now

The approved divestment of Lyka BDR International Limited is expected to simplify Lyka Labs' corporate structure. The company has stated that Lyka BDR International is not a material subsidiary. The Audit Committee has been empowered to finalize the sale terms. This move is part of management's strategy to optimize its business portfolio.

Risks to watch

A key concern highlighted is the negative net worth of Lyka BDR International Limited, which stood at ₹4.49 crore. Investors will need to monitor how this divestment impacts the consolidated balance sheet and the company's overall debt profile. The effectiveness of the merger with Lyka Export Limited will also be crucial.

Peer comparison

While direct, up-to-the-minute peer financial comparisons are not available in the filing, Lyka Labs' reported revenue growth of 45% and profit growth of 159.3% in its segment appear strong on a year-on-year basis. The pharmaceutical and chemical sectors, where Lyka Labs operates, often see varied performance based on product cycles and regulatory environments.

Context metrics (time-bound)

For Q1 FY26 (ended June 30, 2026), Lyka Labs reported standalone revenue of ₹42.31 crore, a 45% increase from ₹29.18 crore in Q1 FY25. Standalone net profit stood at ₹2.10 crore, a 159.3% increase from ₹0.81 crore in Q1 FY25. The divested subsidiary, Lyka BDR International Limited, had a negative net worth of ₹4.49 crore.

What to track next

Investors should closely watch the finalization and execution of the divestment of Lyka BDR International Limited. Monitoring the ongoing integration post-merger with Lyka Export Limited and future quarterly results will be key to assessing the company's sustained growth trajectory and strategic direction.